Lysophosphatidic Acid Receptor 6 Regulated by MiR-27a-3p Attenuates Tumor Proliferation in Breast Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2021 Sep 12

PMID 34510318

Citations 9

Authors

J Lei

S Guo

K Li

J Tian

B Zong

T Ai

Y Peng

Y Zhang

S Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: Lysophosphatidic acid (LPA) is a bioactive molecule which participates in many physical and pathological processes. Although LPA receptor 6 (LPAR6), the last identified LPA receptor, has been reported to have diverse effects in multiple cancers, including breast cancer, its effects and functioning mechanisms are not fully known.

Methods: Multiple public databases were used to investigate the mRNA expression of LPAR6, its prognostic value, and potential mechanisms in breast cancer. Western blotting was performed to validate the differential expression of LPAR6 in breast cancer tissues and their adjacent tissues. Furthermore, in vitro experiments were used to explore the effects of LPAR6 on breast cancer. Additionally, TargetScan and miRWalk were used to identify potential upstream regulating miRNAs and validated the relationship between miR-27a-3p and LPAR6 via real-time polymerase chain reaction and an in vitro rescue assay.

Results: LPAR6 was significantly downregulated in breast cancer at transcriptional and translational levels. Decreased LPAR6 expression in breast cancer is significantly correlated with poor overall survival, disease-free survival, and distal metastasis-free survival, particularly for hormone receptor-positive patients, regardless of lymph node metastatic status. In vitro gain and loss-of-function assays indicated that LPAR6 attenuated breast cancer cell proliferation. The analyses of TCGA and METABRIC datasets revealed that LPAR6 may regulate the cell cycle signal pathway. Furthermore, the expression of LPAR6 could be positively regulated by miR-27a-3p. The knockdown of miR-27a-3p increased cell proliferation, and ectopic expression of LPAR6 could partly rescue this phenotype.

Conclusion: LPAR6 acts as a tumor suppressor in breast cancer and is positively regulated by miR-27a-3p.

Citing Articles

Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response.

Shahrouzi P, Azimzade Y, Brankiewicz-Kopcinska W, Bhatia S, Kunke D, Richard D Breast Cancer Res. 2024; 26(1):170.

PMID: 39605038 PMC: 11600738. DOI: 10.1186/s13058-024-01924-4.

The Effect of Ionizing Irradiation on the Autotaxin-Lysophasphatidic Acid Axis and Interleukin-6/8 Secretion in Different Breast Cancer Cell Lines.

Promny T, Scherrer I, Kadam S, Schmid R, Jost T, Distel L J Pers Med. 2024; 14(9).

PMID: 39338222 PMC: 11433306. DOI: 10.3390/jpm14090968.

Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.

Lee S, Bondaruk J, Wang Y, Chen H, Lee J, Majewski T Cell Rep. 2024; 43(5):114146.

PMID: 38676926 PMC: 11265536. DOI: 10.1016/j.celrep.2024.114146.

The Emerging Role of LPA as an Oncometabolite.

Karalis T, Poulogiannis G Cells. 2024; 13(7.

PMID: 38607068 PMC: 11011573. DOI: 10.3390/cells13070629.

Autotaxin and Lysophosphatidate Signaling: Prime Targets for Mitigating Therapy Resistance in Breast Cancer.

Benesch M, Tang X, Brindley D, Takabe K World J Oncol. 2024; 15(1):1-13.

PMID: 38274724 PMC: 10807915. DOI: 10.14740/wjon1762.

References

Luond F, Tiede S, Christofori G . Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer. 2021; 125(2):164-175. PMC: 8292450. DOI: 10.1038/s41416-021-01328-7. View

Ueda H . Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. Prog Lipid Res. 2020; 81:101079. DOI: 10.1016/j.plipres.2020.101079. View

Geach T, Faas L, Devader C, Gonzalez-Cordero A, Tabler J, Brunsdon H . An essential role for LPA signalling in telencephalon development. Development. 2014; 141(4):940-9. DOI: 10.1242/dev.104901. View

Jendzjowsky N, Roy A, Barioni N, Kelly M, Green F, Wyatt C . Preventing acute asthmatic symptoms by targeting a neuronal mechanism involving carotid body lysophosphatidic acid receptors. Nat Commun. 2018; 9(1):4030. PMC: 6168495. DOI: 10.1038/s41467-018-06189-y. View

Zhao Y, Hasse S, Zhao C, Bourgoin S . Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases. Biochem Pharmacol. 2019; 164:74-81. DOI: 10.1016/j.bcp.2019.03.035. View

Aldi S, Matic L, Hamm G, van Keulen D, Tempel D, Holmstrom K . Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis. Mol Ther Methods Clin Dev. 2018; 10:17-28. PMC: 6039967. DOI: 10.1016/j.omtm.2018.05.003. View

Meduri B, Veeranna Pujar G, Durai Ananda Kumar T, Akshatha H, Sethu A, Singh M . Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development. Eur J Med Chem. 2021; 222:113574. DOI: 10.1016/j.ejmech.2021.113574. View

Lin Y, Lin Y, Chen C . Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials. Cells. 2021; 10(7). PMC: 8306951. DOI: 10.3390/cells10071629. View

Reinartz S, Lieber S, Pesek J, Brandt D, Asafova A, Finkernagel F . Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment. Mol Oncol. 2018; 13(2):185-201. PMC: 6360368. DOI: 10.1002/1878-0261.12396. View

10.

Tao K, Guo S, Chen R, Yang C, Jian L, Yu H . Lysophosphatidic Acid Receptor 6 (LPAR6) Expression and Prospective Signaling Pathway Analysis in Breast Cancer. Mol Diagn Ther. 2019; 23(1):127-138. DOI: 10.1007/s40291-019-00384-3. View

11.

Takahashi K, Fukushima K, Onishi Y, Inui K, Node Y, Fukushima N . Lysophosphatidic acid (LPA) signaling via LPA and LPA negatively regulates cell motile activities of colon cancer cells. Biochem Biophys Res Commun. 2016; 483(1):652-657. DOI: 10.1016/j.bbrc.2016.12.088. View

12.

Xiang H, Lu Y, Shao M, Wu T . Lysophosphatidic Acid Receptors: Biochemical and Clinical Implications in Different Diseases. J Cancer. 2020; 11(12):3519-3535. PMC: 7150451. DOI: 10.7150/jca.41841. View

13.

Pasternack S, von Kugelgen I, Al Aboud K, Lee Y, Ruschendorf F, Voss K . G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008; 40(3):329-34. DOI: 10.1038/ng.84. View

14.

Lippolis R, Gnocchi D, Santacroce L, Siciliano R, Mazzeo M, Scacco S . A distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2020; 526(4):1150-1156. DOI: 10.1016/j.bbrc.2020.04.036. View

15.

Ishii S, Hirane M, Fukushima K, Tomimatsu A, Fukushima N, Tsujiuchi T . Diverse effects of LPA4, LPA5 and LPA6 on the activation of tumor progression in pancreatic cancer cells. Biochem Biophys Res Commun. 2015; 461(1):59-64. DOI: 10.1016/j.bbrc.2015.03.169. View

16.

Mazzocca A, Dituri F, De Santis F, Filannino A, Lopane C, Betz R . Lysophosphatidic acid receptor LPAR6 supports the tumorigenicity of hepatocellular carcinoma. Cancer Res. 2015; 75(3):532-43. DOI: 10.1158/0008-5472.CAN-14-1607. View

17.

Takahashi K, Fukushima K, Otagaki S, Ishimoto K, Minami K, Fukushima N . Effects of LPA and LPA on the regulation of colony formation activity in colon cancer cells treated with anticancer drugs. J Recept Signal Transduct Res. 2018; 38(1):71-75. DOI: 10.1080/10799893.2018.1426608. View

18.

Slack F, Chinnaiyan A . The Role of Non-coding RNAs in Oncology. Cell. 2019; 179(5):1033-1055. PMC: 7347159. DOI: 10.1016/j.cell.2019.10.017. View

19.

Yao X, Tu Y, Xu Y, Guo Y, Yao F, Zhang X . Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages. J Cell Mol Med. 2020; 24(17):9560-9573. PMC: 7520328. DOI: 10.1111/jcmm.15367. View

20.

Hou Y, Fan L, Li H . Oncogenic miR-27a delivered by exosomes binds to SFRP1 and promotes angiogenesis in renal clear cell carcinoma. Mol Ther Nucleic Acids. 2021; 24:92-103. PMC: 7941030. DOI: 10.1016/j.omtn.2020.11.019. View